vitiligo
VITILIGO
Vitiligo is an acquired, often familial, melanocytopenic disorder that produces focal depigmentation of the skin.
About half of the patients has onset of lesion before the age of 20.
It is a progressive disease wherein spontaneous repigmentation may occur within 6 months.
Precipitating factors include emotional stress, sunburn, chemical exposure, skin trauma, inflammation, irritation or rash that may precede the lesions by 2-3 months.
Lesions are white-colored macules or patches with well-defined borders and otherwise normal skin surface.
Drug Information

Indication: Short-term treatment & intermittent long-term therapy of mild to moderate of atopic dermatitis in non-immu...

Indication: Hyperpigmentation conditions eg, chloasma (melasma), freckles & lentigines.

Indication: Hyperpigmentation eg, chloasma, freckles & lentigines.

Indication: Moderate to severe atopic dermatitis in patients who are not adequately responsive to or are intolerant of con...

Indication: Short-term intermittent treatment of moderate to severe facial melasma, in the presence of measures for sun av...

Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 2 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.
3 days ago
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.